Pharma companies need to begin now to strategically plan for 2028–2029 implementation of PBM reforms.

In the final post of our series, we’ll outline some of the key strategic questions that manufacturers must address.

In part three of our series, we explore the effects of the Globe and Guard CMMI MFN demonstration projects and their link to Medicare drug prices.

In part two of this series, we dive into the voluntary Generous CMMI demo and what it means for manufacturers.

In part one of this series, we discuss the avenues that President Trump has looked into in order to engage MFN pricing with the Pharma Industry.

A few key insights from the recent AVBCC panel presentation on ex-U.S. drug access and pricing and how it could Impact MFN in the U.S.

It is time to move beyond DRGs and embrace a new framework to create more sustainable healthcare models.

In this technical review, we will take a look at the unintended consequences of the IRA’s Medicare negotiations on ASP-based Part B in-office administered products.

In this part two, we discuss what is required for success in market access efforts as well as how to avoid common pitfalls.

In this article, we explore an initial impact analysis of Trump's 'Most Favored Nations' executive order which will put enormous pressure on the industry.